10mg/ml 30ml bottle
GW-501516 is a selective agonist (activator) of the PPARδ receptor which regulates fat burning through a number of widespread mechanisms; it increases glucose uptake in skeletal muscle tissue and increases muscle gene expression, especially genes involved in preferential lipid utilization. This shift changes the body’s metabolism to favor burning fat for energy instead of carbohydrates or muscle protein, potentially allowing clinical application for obese patients to lose fat effectively without experiencing muscle catabolism or the effects and satiety issues associated with low blood sugar.
GW-501516 also increases muscle mass, which improved glucose tolerance and reduced fat mass accumulation even in mice fed a very high fat diet, suggesting that GW-501516 may have a protective effect against obesity. Furthermore in rats treated with GW-501516, increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity and type II diabetes was observed. In obese rhesus monkeys, GW-501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.
WARNING: This product, GW-501516 is for research use only. GW-501516 is NOT for human use and can be harmful if ingested into the body. GW-501516 is for research laboratory use only and all GW-501516 dosage amounts for non-human use and only research use must be consulted with by a trained professional. This product is NOT in a sterile solution and is NOT to be injected. GW-501516 should only be handled by licensed, qualified professionals. GW-501516is not a drug, food, or cosmetic and should not be misbranded, misused or mislabeled as a drug, food or cosmetic. GW-501516is a research chemical for research purposes.